Vaxxinity, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VAXX research report →
Price Chart
About the company
Vaxxinity, Inc. , a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses.
- CEO
- Mei Mei Hu
- IPO
- 2021
- Employees
- 57
- HQ
- Merritt Island, FL, US
Get TickerSpark's AI analysis on VAXX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.90M
- P/E
- -30.00
- PEG
- -1.01
- P/S
- 0.00
- P/B
- 0.14
- EV/EBITDA
- -0.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.15%
- ROIC
- -203.71%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,234,000-32.7%
- Op Income
- $-58,285,000
- Net Income
- $-56,934+99.9%
- EPS
- $-0.00+99.9%
- OCF Growth
- -2.3%
- FCF Growth
- -0.4%
- 52W High
- $0.20
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.78
- RSI (14)
- 52
- Avg Volume
- 6.66K
No earnings-call transcripts are available for VAXX yet.
- Free Float
- 47.5%
- Shares Outstanding
- 126.78M
- Float Shares
- 60.28M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VAXX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pathstone Family Office, LLC | 153.85K | 0 |
| Etf Managers Group, LLC | 43.84K | ▲ 12.41K |
Held by 2 ETFs
Biggest fund positions in VAXX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 23 | Ray Sumita | other | 425,000 |
| Nov 3, 23 | Paula Molina Rene | other | 0 |
| Oct 2, 23 | Powchik Peter | other | 159,744 |
| Oct 1, 23 | Ray Sumita | other | 0 |
| Sep 6, 23 | Prime Movers Lab Fund I LP | sell | 5,308 |
| Sep 7, 23 | Prime Movers Lab Fund I LP | sell | 20,312 |
| Sep 8, 23 | Prime Movers Lab Fund I LP | sell | 25,089 |
| Sep 6, 23 | Prime Movers Lab Fund I LP | sell | 2,189 |
| Sep 7, 23 | Prime Movers Lab Fund I LP | sell | 8,378 |
| Sep 8, 23 | Prime Movers Lab Fund I LP | sell | 10,349 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VAXX coverage
Recent articles, reports, and earnings notes.
No research on VAXX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VAXX report →Vaxxinity (NASDAQ:VAXX) and Evotec (OTCMKTS:EVTCY) Head to Head Comparison
defenseworld.net · Feb 26
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
defenseworld.net · Feb 24
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
finbold.com · Jul 4
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
globenewswire.com · Jun 20
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
investorplace.com · May 3
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
investorplace.com · Apr 22
Vaxxinity Issues Shareholder Letter
globenewswire.com · Apr 19
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
globenewswire.com · Apr 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.